Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018” research report to their website http://www.MarketResearchReports.com

Lewes, DE -- (SBWire) -- 04/24/2015 --The global Cushing's Syndrome (CS) treatment market will expand rapidly in value from approximately $179 million in 2013 to $499 million by 2018, representing an impressive Compound Annual Growth Rate (CAGR) of 22.74%, according to new report.

The company's latest report states that of the six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), the US was the largest contributor to CS treatment revenues in 2013, generating around $129 million. The US will see this figure rocket to $371 million by 2018, claiming a 74% share of the global market.

Increasing disease prevalence will be a major driver behind the significant growth in the CS therapeutics arena, along with the arrivals of Novartis' Signifor LAR (pasireotide), a more convenient dosing regimen for Signifor, in the 6MM in 2018 and HRA Pharma's Ketoconazole HRA (ketoconazole) in Europe in 2015.

Senior Analyst covering Cardiovascular & Metabolic Disorders, says: "Additionally, the US launch of second-generation steroidogenesis inhibitors, such as Cortendo AB's NormoCort (COR-003) and Novartis' LCI699, will also boost the market over the forecast period.

"These two drugs will be heralded by physicians and patients alike, as they will satisfy the high unmet need for safer and more effective products targeting CS, namely severe forms of the condition."

Despite these various products' anticipated introductions into their respective markets, GlobalData believes that considerable opportunities remain for pharmaceutical and biotechnology companies to develop improved treatment options.

Senior Analyst continues: "The complex nature and limited understanding of CS, and in particular the pathophysiology behind Cushing's disease, a subtype comprising the majority of CS patients, will continue to hinder the development of efficacious, safe and tolerable agents, especially ones targeting the root cause of Cushing's disease. We therefore don't expect the major unmet need for such drugs to be met fully by the end of the forecast period.

"However, the CS drug landscape is thought to be at a nascent stage of transformation with the arrival of Cortendo AB's NormoCort (COR-003) and Novartis' LCI699, which will provide relief to some concerns over current therapies," the analyst concludes.

OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 report provides annualized Cushing's syndrome (CS) therapeutics market revenues, annual cost of therapies and treatment usage pattern data from 2013 and forecast for five years to 2018. The key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CS therapeutics market.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher's team of industry experts.

For further information on this report, please visit- http://www.marketresearchreports.com/globaldata/opportunityanalyzer-cushing%E2%80%99s-syndrome-opportunity-analysis-and-forecasts-2018

Find all Diseases Reports at: http://www.marketresearchreports.com/diseases

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter